Publications
These are publications from work undertaken by Frontier Science (Scotland).
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Journal of Clinical Oncology, Volume 30, Issue 15, Pages 1879-1887, doi:10.1200/JCO.2011.38.2010,
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
The New England Journal of Medicine, Volume 353, Issue 16, Pages 1659-1672, doi:10.1056/NEJMoa052306,
Management of Data in Clinical Trials, Second Edition
Wiley ,
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial
The Lancet, Volume 379 : 9816 Pages 633-640, doi:10.1016/S0140-6736(11)61847-3,
Analysis of Regional timelines to set up a global phase III Clinical Trial in Breast Cancer: the Adjuvant Lapatinib and/ or Trastuzumab treatment optimization experience
The Oncologist, Volume 18, Issue 2, Pages 134-140, doi:10.1634/theoncologist.2012-0342 ,
Pattern of Rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial
Journal of Clinical Oncology, Volume 31, Issue 36, Pages 4504-4511, doi:10.1200/JCO.2013.50.9448,
CNS Relapses in Patients with HER2-positive early breast cancer who have and who have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)
The Lancet Oncology, Volume 14, Issue 3, Pages 244-248, doi:10.1016/S1470-2045(13)70017-2,
Effect of Age on Breast Cancer outcomes in Women with HER-2 positive Breast Cancer: Results from a Herception Adjuvant Trial
Journal of Clinical Oncology, Volume 31, Issue 21, Pages 2692-2698, doi:10.1200/JCO.2012.44.1956,
PIK3CA Mutations are Associated with reduced pathological complete response rates in primary HER2-positive breast cancer-pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
Annals of Oncology, Volume 27, Issue 8, Pages 1519-1525, doi:10.1093/annonc/mdw197,
Benefit to Neoadjuvant anti-Human Epidermal Growth Factor Receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) Status
Annals of Oncology, Volume 26, Issue 7, Pages 1494-1500, doi:10.1093/annonc/mdv175,